Preclinical experiments with MDM2 inhibitors have shown paradoxical results because they can enhance anti-tumor effects by promoting T lymphocyte proliferation and M1 macrophage polarization, which are inhibited by promoting immune checkpoint expression. The gene discussed is MDM2; the disease is neoplasm.